Filing Details
- Accession Number:
- 0000899243-20-027918
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-10-09 17:23:58
- Reporting Period:
- 2020-10-07
- Accepted Time:
- 2020-10-09 17:23:58
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1731831 | Eidos Therapeutics Inc. | EIDX | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1699848 | Franco Valle | C/O Eidos Therapeutics, Inc. 101 Montgomery Street, Suite 2000 San Francisco CA 94104 | Senior Vice President, Finance | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2020-10-07 | 5,000 | $7.24 | 5,444 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-10-07 | 5,444 | $75.08 | 0 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2020-10-08 | 5,199 | $7.24 | 5,199 | No | 4 | M | Direct | |
Common Stock | Disposition | 2020-10-08 | 5,199 | $74.85 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-10-07 | 5,000 | $0.00 | 5,000 | $7.24 |
Common Stock | Stock Option (Right to Buy) | Disposition | 2020-10-08 | 5,199 | $0.00 | 5,199 | $7.24 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
34,419 | 2028-05-06 | No | 4 | M | Direct | |
29,220 | 2028-05-06 | No | 4 | M | Direct |
Footnotes
- Represents the weighted average sale price of the shares sold from $74.9701 to $75.3901 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1 and 2.
- Represents the weighted average sale price of the shares sold from $74.77 to $74.95 per share.
- The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer.